Complete Filing Data
SNDL Inc. reported Cash And Cash Equivalents of $279.59 million for FY2022.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean SNDL Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Sales And Marketing Expense | $8.4M | $5.0M | $5.7M | $8.1M | $1.3M |
| Research And Development Expense | $2.4M | $2.4M | $488.0K | $2.4M | $413.0K |
| Profit Loss From Operating Activities | -$347.8M | -$134.4M | -$185.4M | -$52.4M | -$12.9M |
| Profit Loss Before Tax | -$379.8M | -$234.7M | -$206.3M | -$146.3M | -$13.0M |
| Profit Loss Attributable To Owners Of Parent | -$335.1M | -$227.0M | -$233.2M | -$271.5M | -$13.0M |
| Profit Loss | -$372.4M | -$226.8M | -$239.9M | -$271.6M | -$13.0M |
| Impairment Loss | $196.0M | $60.0M | $79.2M | $162.0K | $2.2M |
| General And Administrative Expense | $140.2M | $38.0M | $32.0M | $38.9M | $3.1M |
| Comprehensive Income Attributable To Owners Of Parent | -$310.5M | -$219.4M | -$232.6M | -$264.6M | -$13.0M |
| Comprehensive Income | -$347.8M | -$219.2M | -$239.3M | -$264.8M | -$13.0M |
| Profit Loss Attributable To Noncontrolling Interests | -$37.3M | $200.0K | -$6.7M | -$165.0K | |
| Other Comprehensive Income | $24.6M | $7.6M | $600.0K | $6.9M | |
| Gross Profit | $140.4M | -$9.0M | -$49.9M | $36.5M | |
| Comprehensive Income Attributable To Noncontrolling Interests | -$37.3M | $200.0K | -$6.7M | -$165.0K | |
| Adjustments For Income Tax Expense | -$7.3M | -$7.9M | $0.00 | -$3.6M | |
| Profit Loss From Continuing Operations | -$372.4M | -$226.8M | -$206.3M | -$142.7M | |
| Income Loss From Continuing Operations Attributable To Owners Of Parent | -$335.1M | -$227.0M | -$199.6M | -$142.5M | |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | -$43.0M | $32.9M | $0.00 | $0.00 | |
| Profit Loss From Continuing Operations Attributable To Noncontrolling Interests | -$37.3M | $200.0K | -$6.7M | -$165.0K | |
| Gross Revenue | $729.7M | $67.3M | $73.3M | $66.9M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| Cash And Cash Equivalents | $279.6M | $558.3M | $60.4M | $45.3M | $14.1M | $3.7M |
| Biological Assets | $3.5M | $4.4M | $3.5M | $14.3M | $876.0K | |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $10.7M | $3.8M | $3.0M | $110.3M | $7.6M | |
| Gains Losses On Disposals Of Property Plant And Equipment | -$94.0K | $235.0K | $488.0K | $8.0K | -$35.0K | |
| Change In Non Cash Working Capital | -$1.6M | -$348.0K | $2.5M | -$2.1M | -$2.4M | |
| Cash Flows From Used In Operating Activities | -$6.7M | -$155.8M | -$57.5M | -$112.7M | -$5.2M | |
| Cash Flows From Used In Investing Activities | -$230.2M | -$496.3M | -$70.9M | -$213.1M | -$9.7M | |
| Cash Flows From Used In Financing Activities | -$41.8M | $1.15B | $142.7M | $358.3M | $18.9M | |
| Adjustments For Gains Losses On Change In Fair Value Less Costs To Sell Biological Assets | -$1.3M | $4.7M | $5.4M | $30.3M | $366.0K | |
| Adjustments For Gain Loss On Disposals Property Plant And Equipment | -$94.0K | $235.0K | $488.0K | $8.0K | -$35.0K | |
| Retained Earnings | $28.3M | -$785.1M | -$558.1M | -$360.3M | -$88.9M | |
| Issue Of Equity | $2.9M | $977.4M | $176.9M | $198.4M | $8.1M | |
| Financial Asset Marketable Securities Current | $21.9M | $83.7M | $0.00 | $0.00 | ||
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | $28.6M | $82.8M | $0.00 | $77.0M | ||
| Adjustments For Change In Fair Value Of Biological Assets | $1.3M | -$4.7M | -$5.4M | -$30.3M | -$366.0K | |
| Trade And Other Receivables | $22.6M | $10.9M | $15.9M | $27.6M | $2.7M | |
| Trade And Other Payables | $48.2M | $38.5M | $23.3M | $58.1M | $19.3M | |
| Restricted Cash And Cash Equivalents | $19.3M | $27.0M | $5.3M | $15.8M | $350.0K | |
| Purchase Of Intangible Assets Classified As Investing Activities | $197.0K | $0.00 | $150.0K | $0.00 | ||
| Property Plant And Equipment | $143.4M | $56.5M | $116.9M | $282.0M | $88.5M | |
| Noncurrent Lease Liabilities | $139.6M | $27.8M | $1.0M | $16.2M | $170.0K | |
| Liabilities | $231.7M | $98.1M | $25.2M | $288.8M | $118.1M | |
| Goodwill | $67.3M | $72.5M | $11.4M | |||
| Equity Attributable To Owners Of Parent | $1.31B | $1.33B | $271.7M | $216.5M | -$7.9M | |
| Equity And Liabilities | $1.56B | $1.43B | $294.9M | $510.0M | $110.2M | |
| Current Liabilities | $89.4M | $65.9M | $24.1M | $269.2M | $69.7M | |
| Current Lease Liabilities | $30.2M | $5.7M | $409.0K | $722.0K | $44.0K | |
| Current Assets | $501.5M | $728.2M | $118.4M | $172.6M | $21.7M | |
| Cash Flows From Used In Operating Activities Continuing Operations | -$6.7M | -$155.8M | -$62.3M | -$99.8M | ||
| Assets | $1.56B | $1.43B | $294.9M | $510.0M | $110.2M | |
| Adjustments For Decrease Increase In Inventory Obsolescence | $7.0M | $17.0M | $45.9M | $0.00 | ||
| Intangible Assets Other Than Goodwill | $74.9M | $50.1M | $5.1M | $44.0M | ||
| Income Distributions From Equity Accounted Investees | -$1.7M | -$15.0M | $0.00 | $0.00 | ||
| Cash Flows From Used In Operating Activities Discontinued Operations | $0.00 | $0.00 | $4.8M | -$12.9M | ||
| Adjustments For Unrealized Gain Loss On Marketable Securities | $65.6M | $64.7M | $0.00 | $0.00 |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Payments Of Lease Liabilities Classified As Financing Activities | $27.7M | $1.0M | $420.0K | $292.0K | $109.0K |
| Increase Decrease In Working Capital | $22.1M | -$150.0K | $5.3M | $41.6M | -$910.0K |
| Increase Decrease In Non Cash Working Capital Classified As Investing Activities | -$74.0K | $612.0K | $11.3M | -$1.7M | $2.1M |
| Increase Decrease In Cash And Cash Equivalents | -$278.7M | $497.9M | $15.0M | $31.2M | $4.0M |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | $4.0M | $194.0K | $2.1M | $51.0K | $30.0K |
| Increase Decrease In Restricted Cash From Financing Activities | -$7.7M | $21.7M | -$10.5M | $15.5M | |
| Proceeds From Issuing Shares | 22.0K | 1.06B | 181.8M | 177.2M | 9.6M |
| Proceeds From Issue Of Bonds Notes And Debentures | $0.00 | $0.00 | $18.1M | $90.4M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Increase Decrease Through Sharebased Payment Transactions | $11.0M | $12.7M | $7.7M | $39.5M | $4.6M |
| Expense From Sharebased Payment Transactions With Employees | $9.7M | $12.3M | $8.6M | $38.7M | $4.6M |
| Depreciation And Amortisation Expense | $40.9M | $5.3M | $4.7M | $595.0K | $411.0K |
| Adjustments For Sharebased Payments | $9.7M | $12.3M | $8.6M | $38.7M | $4.6M |
| Adjustments For Depreciation And Amortisation Expense | $47.3M | $10.2M | $11.6M | $6.3M | $411.0K |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -$16.0K | -$63.0K | -$757.0K | $671.0K | |
| Finance Costs | $41.3M | $3.8M | $3.8M | $24.2M | $75.0K |
| Warrants | $2.3M | $8.1M | $6.1M | $27.8M | $3.1M |
| Prepayments | $10.1M | $4.4M | $4.6M | $9.6M | $2.4M |
| Other Reserves | $69.0M | $60.7M | $59.3M | $30.2M | $9.5M |
| Issued Capital | $2.29B | $2.04B | $762.0M | $509.7M | $65.1M |
| Inventories | $127.8M | $29.5M | $25.6M | $59.9M | $1.2M |
| Adjustments For Gains Losses On Change In Fair Value Of Derivatives | $10.8M | -$77.8M | -$13.0M | $0.00 | |
| Adjustment For Finance Costs | $41.3M | $3.7M | -$3.7M | $11.1M | |
| Transaction Costs | $1.4M | $17.6M | $3.6M | $8.5M |
Most recent annual filing with the SEC: April 24, 2023
Data sourced from SEC EDGAR public filings as of August 7, 2026.